Telomir Pharmaceuticals Enters Material Definitive Agreement
Ticker: TELO · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1971532
Sentiment: neutral
Topics: material-definitive-agreement, pharmaceuticals
TL;DR
Telomir Pharma signed a big deal on Oct 17th. Details to follow.
AI Summary
On October 17, 2025, Telomir Pharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Florida with its principal executive offices in Miami, operates in the Pharmaceutical Preparations industry. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
This filing indicates a significant new agreement for Telomir Pharmaceuticals, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not yet detailed in this initial filing.
Key Numbers
- 001-41952 — SEC File Number (Identifies the company's filing with the SEC.)
- 87-2606031 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- October 17, 2025 (date) — Date of earliest event reported
- Florida (location) — State of Incorporation
- Miami (location) — Address of Principal Executive Offices
- 2834 (industry_code) — Standard Industrial Classification
FAQ
What is the nature of the material definitive agreement entered into by Telomir Pharmaceuticals?
The filing states that Telomir Pharmaceuticals, Inc. entered into a material definitive agreement on October 17, 2025, but the specific details of this agreement are not provided in this initial 8-K filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 17, 2025.
Where are Telomir Pharmaceuticals' principal executive offices located?
Telomir Pharmaceuticals' principal executive offices are located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida 33131.
What is Telomir Pharmaceuticals' Standard Industrial Classification code?
Telomir Pharmaceuticals' Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
What is the SEC file number for Telomir Pharmaceuticals?
The SEC file number for Telomir Pharmaceuticals, Inc. is 001-41952.
Filing Stats: 798 words · 3 min read · ~3 pages · Grade level 13.5 · Accepted 2025-10-20 16:01:44
Key Financial Figures
- $5 million — ing global IP rights and enabling up to $5 million in potential shareholder contributions,
- $1 million — ment activities, structured as follows: $1 million at closing, $2 million upon FDA accepta
- $2 million — ured as follows: $1 million at closing, $2 million upon FDA acceptance of an Investigation
- $4 million — 1/2 study. Shares corresponding to the $4 million in milestone contributions will be allo
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex10-1.htm (EX-10.1) — 43KB
- 0001493152-25-018634.txt ( ) — 254KB
- telo-20251017.xsd (EX-101.SCH) — 3KB
- telo-20251017_lab.xml (EX-101.LAB) — 33KB
- telo-20251017_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Dated: October 20, 2025 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer